RecruitingNCT04569448
Brexpiprazole Treatment for Bipolar I Depression
Medication studyAges 18–75CanadaBipolarity
Understand this study
Who could participate?
Listed age limits: 18 years to 75 years.
What will I do during this study?
The study examines add-on brexpiprazole at a variable dose for people with bipolarity who are experiencing a depressive episode. The public record reviewed does not specify the treatment duration or visit schedule.
- Listed locations
- Hamilton and 2 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: May 10, 2021
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 58
- Sponsor
- Douglas Mental Health University Institute
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- Canada
- Age range
- From 18 Years to 75 Years
- Official registry ID
- NCT04569448
- Official title
Show the full official title
Low-Dose Adjunctive Brexpiprazole in the Treatment of Bipolar I Depression: An Open-Label Study
Recruitment & locations
Currently recruitingA study may be recruiting, but some locations may no longer be accepting participants. Confirm availability with the research team.
Hamilton · Montreal
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Douglas Mental Health University Institute, a university.
Does this study involve medication?
Yes. The study involves medication, including Brexpiprazole.
Who can participate?
Listed age limits: 18 years to 75 years.
Is this study still recruiting?
The registry lists this study as recruiting.
